[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

It has been a strange year for the U.S. stock market. The S&P 500 ($SPX) is up about 10% so far, but most of that gain has come from just 23 stocks, mainly in AI and energy. The rest of the market has barely moved. When gains are this concentrated, it often makes investors cautious and pushes them toward safer, dividend-paying stocks.

One name standing out in that shift is Merck & Co. (MRK). The stock is up 19% year-to-date (YTD), beating the S&P 500’s 10% return over the same period. Moreover, Merck pays a steady quarterly dividend of $0.85 per...

Fundamentals

See More
  • Market Capitalization, $K 311,173,120
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.19
  • Price/Sales 4.90
  • Price/Cash Flow 11.28
  • Price/Book 6.93

Options Overview Details

View History
  • Implied Volatility 31.86% (-0.37%)
  • Historical Volatility 31.83%
  • IV Percentile 80%
  • IV Rank 74.15%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 7) 3.74 (2.99%)
  • Put/Call Vol Ratio 1.12
  • Today's Volume 10,446
  • Volume Avg (30-Day) 26,844
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 436,604
  • Open Int (30-Day) 454,716
  • Expected Range 121.33 to 128.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.15
  • Number of Estimates 3
  • High Estimate $2.18
  • Low Estimate $2.10
  • Prior Year $2.13
  • Growth Rate Est. (year over year) +0.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.57 +12.10%
on 06/18/26
130.29 -4.01%
on 06/30/26
+5.47 (+4.57%)
since 06/09/26
3-Month
107.90 +15.91%
on 04/29/26
130.29 -4.01%
on 06/30/26
+2.39 (+1.95%)
since 04/09/26
52-Week
76.66 +63.15%
on 07/29/25
130.29 -4.01%
on 06/30/26
+41.36 (+49.41%)
since 07/09/25

Most Recent Stories

More News
This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

GOOG : 356.24 (-0.69%)
GOOGL : 358.89 (-0.84%)
$SPX : 7,543.64 (+0.81%)
MRK : 125.07 (-0.73%)
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on...

MRK : 125.07 (-0.73%)
Futures Rise Day Before Canada Day

Canadian stock index futures rose on Tuesday, as higher commodity prices and easing geopolitical tensions ...

MRK : 125.07 (-0.73%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 43.00 (+2.70%)
AZN : 178.49 (-5.70%)
MRK : 125.07 (-0.73%)
GILD : 134.84 (-0.72%)
TEM : 61.50 (+7.39%)
GSK : 52.47 (-0.10%)
ARKK : 81.53 (+1.71%)
BMY : 57.94 (+0.70%)
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Agreement will help state ADAP programs provide access to IDVYNSOâ„¢ (doravirine/islatravir) for eligible individuals

MRK : 125.07 (-0.73%)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

First approval of PD‑1 inhibitors in combination with a Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option

MRK : 125.07 (-0.73%)
How to Buy Merck Stock for a 10% Discount or Achieve an 11% Annual Return

On Monday, with Merck trading at $119.60, the August put option with a strike price of $110 was trading around $2.03. Traders selling this put would receive $230 in option premium. In return for receiving...

MRK : 125.07 (-0.73%)
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Approval based on results from the Phase 3 KEYNOTE-905 trial in which perioperative KEYTRUDA plus Padcev reduced the risk of event-free survival events by 60% and risk of death by 50% versus surgery alone...

MRK : 125.07 (-0.73%)
Short Straddle Screener Results for June 23rd

A short straddle is an advanced options strategy used when a trader is seeking to profit from an underlying stock trading in a narrow range.

MSFT : 384.36 (+0.27%)
TSLA : 406.55 (+3.17%)
SPCX : 152.16 (+2.60%)
MRK : 125.07 (-0.73%)
PLTR : 129.04 (-2.41%)
CRM : 162.50 (-2.45%)
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a Phase 3 trial Tulisokibart...

MRK : 125.07 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 130.90
2nd Resistance Point 129.49
1st Resistance Point 127.28
Last Price 125.07
1st Support Level 123.65
2nd Support Level 122.24
3rd Support Level 120.03

See More

52-Week High 130.29
Last Price 125.07
Fibonacci 61.8% 109.80
Fibonacci 50% 103.47
Fibonacci 38.2% 97.15
52-Week Low 76.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.